RxDoctor Payments Data

Julije Vucemilovic, MD

Family Medicine · Saint Petersburg, FLNPI 1053318329

Payments from drug & device makers

$1,374in general payments, 2019–2025

Across 48 payments — averaging $28.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$271
  • Eisai Inc.$236
  • Lilly USA, LLC$200
  • Amarin Pharma, Inc.$173
  • GSK$144
  • Esperion Therapeutics, Inc.$109
  • plus $240 from 7 others

What the payments were for

  • Food & beverage$1,36099%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,374 in reported general payments places this provider in the 65th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$467,329
Medicare patients
256
Services billed
4,090

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide111$114,038
JardianceEmpagliflozin67$87,775
EliquisApixaban30$32,900
FarxigaDapagliflozin Propanediol25$28,411
VascepaIcosapent Ethyl37$21,354
OzempicSemaglutide11$10,484
XareltoRivaroxaban13$7,286
Rosuvastatin Calcium275$3,837
Albuterol Sulfate HfaAlbuterol Sulfate75$2,803
Atorvastatin Calcium225$2,092
Levothyroxine Sodium259$2,064
SynthroidLevothyroxine Sodium21$1,995
Lisinopril287$1,852
Omeprazole84$1,668
Ezetimibe64$1,601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$200$114,038111 claims
Boehringer IngelheimJardiance$271$87,77567 claims
PfizerEliquis$14$32,90030 claims
Novo NordiskOzempic$71$10,48411 claims
Johnson & JohnsonXarelto$29$7,28613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Saint Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →